HROW

NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Dollar change +0.81
Percentage change 3.43	%

Peers: OCUL EYPT PRPH AKTX ALDX EDIT QURE TTOO CRSP BNGO

| Held by: VTI IWM VXF IWO VTWO SCHA VHT XPH IHE IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.61	Insider Own	15.98%	Shs Outstand	35.65M	Perf Week	-5.55%
Market Cap	895.47M	Forward P/E	14.17	EPS next Y	1.72	Insider Trans	-0.59%	Shs Float	30.83M	Perf Month	-2.05%
Income	-21.70M	PEG	-	EPS next Q	0.06	Inst Own	56.52%	Short Float	12.28%	Perf Quarter	-21.32%
Sales	212.86M	P/S	4.21	EPS this Y	188.98%	Inst Trans	-1.83%	Short Ratio	7.39	Perf Half Y	-46.72%
Book/sh	1.58	P/B	15.41	EPS next Y	295.07%	ROA	-6.58%	Short Interest	3.79M	Perf Year	123.03%
Cash/sh	1.82	P/C	13.42	EPS next 5Y	-	ROE	-37.23%	52W Range	10.08 - 59.23	Perf YTD	-27.27%
Dividend Est.	-	P/FCF	2132.07	EPS past 5Y	-	ROI	-12.22%	52W High	-58.80%	Beta	0.36
Dividend TTM	-	Quick Ratio	0.85	Sales past 5Y	33.27%	Gross Margin	74.53%	52W Low	142.06%	ATR (14)	1.88
Dividend Ex-Date	-	Current Ratio	0.91	EPS Y/Y TTM	33.82%	Oper. Margin	2.24%	RSI (14)	48.31	Volatility	9.09% 6.68%
Employees	382	Debt/Eq	4.07	Sales Y/Y TTM	53.49%	Profit Margin	-10.19%	Recom	1.00	Target Price	54.84
Option/Short	Yes / Yes	LT Debt/Eq	2.14	EPS Q/Q	-29.79%	Payout	-	Rel Volume	2.50	Prev Close	23.59
Sales Surprise	-16.08%	EPS Surprise	-986.96%	Sales Q/Q	38.29%	Earnings	May 08 AMC	Avg Volume	512.38K	Price	24.40
SMA20	0.29%	SMA50	-2.27%	SMA200	-31.22%	Trades		Volume	1,280,866	Change	3.43%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-06-25	Initiated	H.C. Wainwright	Buy	$57
Dec-04-24	Reiterated	B. Riley Securities	Buy	$73 → $69
Apr-11-24	Initiated	Craig Hallum	Buy	$24
Sep-08-22	Resumed	B. Riley Securities	Buy	$17
Oct-14-21	Resumed	B. Riley Securities	Buy	$16
Sep-24-21	Initiated	Aegis Capital	Buy	$15
Jul-02-21	Initiated	Ladenburg Thalmann	Buy	$14.25

Today 03:03AM	Harrow Inc (HROW) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Market ... (GuruFocus.com)
May-08-25 05:10PM	Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Harrow Announces First-Quarter 2025 Financial Results (Business Wire)
09:32AM	Harrow Inc (HROW) Q1 2025 Earnings Report Preview: What to Look For (GuruFocus.com)
May-07-25 10:28AM	What To Expect From Harrow Inc (HROW) Q1 2025 Earnings (GuruFocus.com)
07:00AM	Loading…
May-05-25 07:00AM	Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025 (Business Wire)
Apr-30-25 07:35AM	United Therapeutics (UTHR) Q1 Earnings and Revenues Top Estimates (Zacks)
Apr-29-25 07:35AM	What Recession? I'm Swimming In Dividends (Seeking Alpha)
Apr-24-25 10:00AM	NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension) (PR Newswire) +5.20%
Apr-21-25 04:26PM	Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... (GuruFocus.com)
Apr-10-25 07:00AM	Harrow Expands VEVYE Access for All Program to ImprimisRxs Klarity-C Patients (Business Wire) -5.76%
Mar-29-25 04:30PM	Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade) (Seeking Alpha)
03:01PM	Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives (GuruFocus.com)
Mar-28-25 02:00PM	Harrow, Inc. (HROW) Q4 2024 Earnings Conference Call (Seeking Alpha) -5.96%
01:39PM	Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp (Seeking Alpha)
06:45PM	Loading…
Mar-27-25 06:45PM	Harrow (HROW) Q4 Earnings and Revenues Top Estimates (Zacks)
04:01PM	Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results (Business Wire)
10:45AM	Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025 (Business Wire)
Mar-24-25 07:00AM	Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL (Business Wire) +5.60%
Mar-21-25 10:56PM	What To Expect From Harrow Inc (HROW) Q4 2024 Earnings (GuruFocus.com)
Mar-19-25 05:18PM	Harrow: A Name I Am Accumulating (SeekingAlpha)
Mar-17-25 04:01PM	Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance (Business Wire) +15.69%
07:00AM	Harrow Launches VEVYE Access for All (Business Wire)
Mar-11-25 07:00AM	Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE (Business Wire)
Mar-03-25 07:15AM	Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025 (Business Wire) -8.73%
Feb-07-25 09:40AM	Reddit initiated, Cigna downgraded: Wall Streets top analyst calls (TipRanks)
Jan-27-25 07:30AM	Harrow Partners with Cencora to Launch Harrow Cares Program, Making IHEEZO and TRIESENCE More Accessible and Affordable for Retina Specialists and Their Patients (Business Wire)
Jan-07-25 07:00AM	Harrow Appoints Amir H. Shojaei as Chief Scientific Officer (Business Wire)
Nov-21-24 07:00AM	Harrows ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc. (Business Wire)
Nov-20-24 07:00AM	Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery (Business Wire) +6.90%
07:00AM	Loading…
Nov-15-24 07:00AM	Harrow Announces Participation in Upcoming Investor Conferences (Business Wire) -8.98%
02:06AM	Harrow Inc (HROW) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ... (GuruFocus.com)
Nov-13-24 04:34PM	Harrow Announces Third Quarter 2024 Financial Results (Business Wire) -17.26%
07:16AM	Harrow Inc (HROW) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
07:00AM	Harrow Launches Access and Affordability Program with Price Reductions for Branded Products (Business Wire)
Nov-12-24 07:00AM	Harrow Announces Market Access Wins for VEVYE (Business Wire)
Nov-07-24 07:00AM	Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrows Branded Eyecare Products (Business Wire)
Oct-31-24 07:00AM	Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024 (Business Wire)
Oct-10-24 07:00AM	Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery (Business Wire)
Oct-03-24 07:00AM	Harrow Relaunches TRIESENCE (Business Wire) +8.44%
Oct-02-24 11:10AM	Harrow, Inc. (HROW): A Bull Case Theory (Insider Monkey)
Sep-25-24 12:02PM	Harrow Announces Nashville Expansion (Business Wire)
Sep-03-24 07:00AM	Harrow to Present at Three Investor Conferences in September in New York (Business Wire)
Aug-07-24 04:01PM	Harrow Announces Second Quarter 2024 Financial Results (Business Wire) +54.32%
Jul-25-24 07:00AM	Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024 (Business Wire)
Jul-12-24 07:00AM	Harrow to Attend 2024 ASRS Annual Meeting (Business Wire)
Jul-09-24 07:00AM	Harrow Enters into 340B Prime Vendor Program Contract with Apexus for IHEEZO and Other Key Harrow Products (Business Wire)
Jul-02-24 11:52AM	HROW Stock Earnings: Harrow Beats EPS, Beats Revenue for Q2 2023 (InvestorPlace)
Jun-20-24 07:00AM	Harrow Provides TRIESENCE Relaunch Update (Business Wire) +12.92%
Jun-07-24 06:30AM	The Top 7 Growth Stocks to Buy and Hold Until 2030 (InvestorPlace)
Jun-06-24 08:00AM	Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery (Business Wire)
Jun-05-24 07:00AM	Harrow Announces 52-Week Data from VEVYE ESSENCE-2 Open-Label Extension Study (Business Wire)
May-15-24 07:00AM	Harrow to Present at Two Investor Conferences in May (Business Wire)
May-13-24 08:55PM	HROW Stock Earnings: Harrow Health Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) +34.55%
04:25PM	Harrow Health Q1 Core Net Loss Widens, Revenue Increases -- Shares Rise After-Hours (MT Newswires)
04:01PM	Harrow Announces First Quarter 2024 Financial Results (Business Wire)
07:00AM	Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial (Business Wire)
Apr-25-24 07:00AM	Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024 (Business Wire)
Apr-02-24 08:16AM	Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing (Business Wire)
Mar-21-24 09:55AM	Harrow Health, Inc. (NASDAQ:HROW) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-19-24 09:52PM	HROW Stock Earnings: Harrow Health Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
06:51PM	Harrow Inc (HROW) Reports Substantial Revenue Growth Amidst Net Loss Expansion in 2023 (GuruFocus.com)
05:45PM	Harrow Announces Fourth Quarter and Year-End 2023 Financial Results (Business Wire)
Mar-13-24 06:35AM	Harrow (HROW) Fell on Lowering the Guidance (Insider Monkey)
Mar-05-24 07:00AM	Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024 (Business Wire)
Mar-04-24 08:28PM	11 Best Small Cap Pharma Stocks to Invest In (Insider Monkey)
Feb-21-24 06:47AM	Heres How Harrow (HROW) Weighed on SRK Capitals Performance (Insider Monkey)
Feb-15-24 04:01PM	Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products (Business Wire)
Jan-29-24 07:00AM	Harrow Announces New Appointments to its Board of Directors (Business Wire)
Jan-11-24 07:00AM	Harrow Announces Availability of VEVYE (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease (Business Wire)
Jan-03-24 07:15AM	Melt Pharmaceuticals Provides Corporate Update (Business Wire)
07:00AM	Harrow Partners with Leading Healthcare Market Access Technology Platforms (Business Wire)
Dec-24-23 01:08PM	7 Short-Squeeze Stocks That Are Screaming for Speculation (InvestorPlace)
Nov-29-23 07:00AM	Harrow Completes Transfer of the TRIESENCE New Drug Application (Business Wire)
Nov-20-23 07:00AM	Harrow to Present at Two Investor Conferences in November (Business Wire) +5.58%
Nov-14-23 12:56PM	Harrow Health, Inc. (NASDAQ:HROW) Q3 2023 Earnings Call Transcript (Insider Monkey) -36.01%
Nov-13-23 05:07PM	Harrow Inc (HROW) Reports 50% Revenue Growth in Q3 2023 (GuruFocus.com)
04:01PM	Harrow Announces Third Quarter 2023 Financial Results (Business Wire)
Oct-30-23 08:00AM	Harrow Will Release Third Quarter 2023 Financial Results on November 13, 2023 (Business Wire)
Oct-24-23 07:00AM	Harrow Completes Transfer of NDAs and Launches FLAREX, NATACYN, TOBRADEX ST, VERKAZIA, and ZERVIATE in the U.S. (Business Wire)
Sep-29-23 08:00AM	Harrow Health, Inc. Changes Corporate Name to Harrow, Inc. (Business Wire)
Sep-26-23 08:00AM	Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation (Business Wire) -5.20%
Sep-21-23 01:03PM	Opaleye Management Inc. Reduces Stake in Harrow Health Inc. (GuruFocus.com)
Aug-11-23 01:05PM	Harrow Health, Inc. (NASDAQ:HROW) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-10-23 09:54AM	Q2 2023 Harrow Health Inc Earnings Call (Thomson Reuters StreetEvents) -15.45%
Aug-09-23 04:14PM	Harrow: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Harrow Announces Second Quarter 2023 Financial Results (Business Wire)
Jul-31-23 07:00AM	Harrow Launches VIGAMOX® in the U.S. (Business Wire)
Jul-28-23 02:56PM	10 Best Small Cap Pharma Stocks to Buy (Insider Monkey)
Jul-26-23 03:42PM	Harrow Health inks deals for the rights to eight medications (American City Business Journals)
09:00AM	Harrow to Announce Second Quarter 2023 Financial Results on August 9, 2023 (Business Wire)
Jul-20-23 10:29AM	Strength Seen in Harrow (HROW): Can Its 17.8% Jump Turn into More Strength? (Zacks)
Jul-19-23 12:17PM	Why Shares of Harrow Health Are Jumping Wednesday (Motley Fool) +17.84%
07:00AM	Harrow Prices $60 Million Public Offering of Common Stock (Business Wire)
Jul-18-23 05:00PM	Harrow Acquires Santens Branded Ophthalmic Portfolio (Business Wire)
04:05PM	Harrow Provides Select Preliminary Second Quarter 2023 Financial Guidance (Business Wire)
04:04PM	Harrow Announces Proposed Public Offering of Common Stock (Business Wire)
04:01PM	Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq (Business Wire)
Jul-05-23 06:15PM	Harrow Health (HROW) Gains As Market Dips: What You Should Know (Zacks)
Jun-29-23 06:15PM	Harrow Health (HROW) Outpaces Stock Market Gains: What You Should Know (Zacks) +6.31%

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BOLL ANDREW R.	Chief Financial Officer	Apr 03 '25	Option Exercise	0.00	346,500	0	914,589	Apr 07 09:55 PM
SAHAREK JOHN P.	CEO & President, ImprimisRx	Apr 03 '25	Option Exercise	0.00	277,200	0	576,863	Apr 07 09:54 PM
BAUM MARK L	Chief Executive Officer	Apr 03 '25	Option Exercise	0.00	762,300	0	2,899,825	Apr 07 09:54 PM
Opaleye Management Inc.	10% Owner	Mar 18 '25	Sale	30.01	5,000	150,055	140,000	Mar 26 04:05 PM
Opaleye Management Inc.	10% Owner	Mar 18 '25	Sale	29.64	5,000	148,200	145,000	Mar 20 04:05 PM
Opaleye Management Inc.	10% Owner	Feb 28 '25	Sale	28.05	5,000	140,250	150,000	Mar 04 04:44 PM
Opaleye Management Inc.	10% Owner	Jan 22 '25	Sale	35.59	20,000	711,814	155,000	Jan 24 09:29 PM
SAHAREK JOHN P.	CEO of ImprimisRx	Sep 11 '24	Option Exercise	7.37	90,000	663,300	344,803	Sep 13 05:26 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Harrow Inc

Upgrade your FINVIZ experience